Author/Authors :
Sanchez، نويسنده , , Ramon and Williams، نويسنده , , Christopher and Daza، نويسنده , , Jose L. and Dan، نويسنده , , Qinghong and Xu، نويسنده , , Qingcheng and Chen، نويسنده , , Yijun and Delgado، نويسنده , , Christina and Arpajirakul، نويسنده , , Neary and Jeffes، نويسنده , , Edward W.B. and Kim، نويسنده , , Ronald C. and Douglass، نويسنده , , Thomas and Al Atar، نويسنده , , Usama and Terry Wepsic، نويسنده , , H. and Jadus، نويسنده , , Martin R.، نويسنده ,
Abstract :
Cloned T9 glioma cells (T9-C2) expressing the membrane form of macrophage colony stimulating factor (mM-CSF) inoculated subcutaneously into rats do not grow and glioma-specific immunity is stimulated. Immunotherapy experiments showed that intracranial T9 tumors present for one to four days could be successfully eradicated by peripheral vaccination with T9-C2 cells. CD4+ and CD8+ T splenocytes from immunized rats, when restimulated in vitro with T9 cells, produced interleukin-2 and -4. Protective immunity against intracranial T9 gliomas could only be adoptively transferred into naive rats by the CD4+ splenocytes obtained from T9-C2 immunized rats. Rats immunized by the T9-C2 tumor cells also resisted two different syngeneic gliomas (RT2 and F98) but allowed a syngeneic NUTU-19 ovarian cancer to grow. Such cross-protective immunity against unrelated gliomas suggests that mM-CSF transfected tumor cells have immunotherapeutic potential for use as an allogeneic tumor vaccine.
Keywords :
Macrophage colony stimulating factor , Membrane-bound cytokine , macrophages , Glioma , Tumor vaccine , epitope spreading , POLYMERASE CHAIN REACTION , CD4+ T cells , Intracellular flow cytometry
